Erschienen in:
22.07.2019 | Hepatitis B (JK Lim, Section Editor)
Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues
verfasst von:
Zaid H. Tafesh, Robert S. Brown Jr
Erschienen in:
Current Hepatology Reports
|
Ausgabe 3/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose of the Review
Poorly controlled hepatitis B increases the risk for liver-related morbidity. Although there are now six approved nucleos(t)ide analogues (NA) for the treatment of chronic hepatitis B (CHB), drug resistance and thus virologic breakthrough still exist. This review outlines a systematic approach to the management of virologic failure in patients with CHB treated with NAs.
Recent Findings
Current NAs can be divided into older generation and newer generation agents, with newer generation agents associated with lower rates of virologic breakthrough. Both tenofovir dipovoxil fumarate (TDF) and tenofovir alafenamide (TAF) are equally as effective in addressing virologic breakthrough while on all other NAs. Entecavir is an effective treatment option for NA naïve patients only, with high rates of resistance to entecavir in those exposed to older NAs.
Summary
The management of virologic breakthroughs should focus on identifying risk factors for future drug resistance and escalation to appropriate newer generation drug options to avoid long-term liver-related morbidity.